Vanda Pharmaceuticals (VNDA) Competitors $4.61 -0.12 (-2.44%) As of 03:14 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock VNDA vs. OPK, GERN, RIGL, ZBIO, MYGN, VSTM, EBS, LXRX, XOMA, and CBIOShould you be buying Vanda Pharmaceuticals stock or one of its competitors? The main competitors of Vanda Pharmaceuticals include OPKO Health (OPK), Geron (GERN), Rigel Pharmaceuticals (RIGL), Zenas BioPharma (ZBIO), Myriad Genetics (MYGN), Verastem (VSTM), Emergent Biosolutions (EBS), Lexicon Pharmaceuticals (LXRX), XOMA Royalty (XOMA), and Crescent Biopharma (CBIO). These companies are all part of the "biotechnology" industry. Vanda Pharmaceuticals vs. Its Competitors OPKO Health Geron Rigel Pharmaceuticals Zenas BioPharma Myriad Genetics Verastem Emergent Biosolutions Lexicon Pharmaceuticals XOMA Royalty Crescent Biopharma Vanda Pharmaceuticals (NASDAQ:VNDA) and OPKO Health (NASDAQ:OPK) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, media sentiment, profitability, valuation and dividends. Which has more volatility & risk, VNDA or OPK? Vanda Pharmaceuticals has a beta of 0.74, suggesting that its share price is 26% less volatile than the S&P 500. Comparatively, OPKO Health has a beta of 1.4, suggesting that its share price is 40% more volatile than the S&P 500. Is VNDA or OPK more profitable? OPKO Health has a net margin of -26.68% compared to Vanda Pharmaceuticals' net margin of -32.90%. Vanda Pharmaceuticals' return on equity of -12.89% beat OPKO Health's return on equity.Company Net Margins Return on Equity Return on Assets Vanda Pharmaceuticals-32.90% -12.89% -10.47% OPKO Health -26.68%-13.17%-8.28% Which has preferable earnings & valuation, VNDA or OPK? Vanda Pharmaceuticals has higher earnings, but lower revenue than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVanda Pharmaceuticals$198.77M1.35-$18.90M-$1.13-4.03OPKO Health$713.10M1.53-$53.22M-$0.25-5.50 Do analysts prefer VNDA or OPK? Vanda Pharmaceuticals currently has a consensus target price of $16.50, suggesting a potential upside of 262.24%. OPKO Health has a consensus target price of $2.75, suggesting a potential upside of 100.00%. Given Vanda Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Vanda Pharmaceuticals is more favorable than OPKO Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vanda Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50OPKO Health 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.83 Do insiders and institutionals hold more shares of VNDA or OPK? 88.1% of Vanda Pharmaceuticals shares are owned by institutional investors. Comparatively, 64.6% of OPKO Health shares are owned by institutional investors. 8.9% of Vanda Pharmaceuticals shares are owned by company insiders. Comparatively, 49.7% of OPKO Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the media favor VNDA or OPK? In the previous week, Vanda Pharmaceuticals and Vanda Pharmaceuticals both had 6 articles in the media. OPKO Health's average media sentiment score of 1.41 beat Vanda Pharmaceuticals' score of 0.75 indicating that OPKO Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vanda Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive OPKO Health 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryOPKO Health beats Vanda Pharmaceuticals on 9 of the 15 factors compared between the two stocks. Get Vanda Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VNDA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VNDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VNDA vs. The Competition Export to ExcelMetricVanda PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$269.16M$3.10B$5.75B$9.87BDividend YieldN/A2.28%6.66%4.49%P/E Ratio-4.0320.8082.8226.56Price / Sales1.35372.93500.42162.62Price / CashN/A43.5325.7028.92Price / Book0.558.0510.796.50Net Income-$18.90M-$53.35M$3.28B$266.21M7 Day Performance-3.09%-0.80%-0.25%-1.06%1 Month Performance6.92%6.16%6.71%3.51%1 Year Performance-10.33%11.03%49.66%23.94% Vanda Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VNDAVanda Pharmaceuticals4.1268 of 5 stars$4.61-2.4%$16.50+258.3%-7.1%$271.52M$198.77M-4.07290OPKOPKO Health4.3971 of 5 stars$1.38-2.8%$2.75+99.3%-14.8%$1.10B$713.10M-5.522,997Positive NewsGERNGeron3.2222 of 5 stars$1.40-2.1%$4.19+199.1%-68.2%$893.22M$76.99M-10.77229RIGLRigel Pharmaceuticals2.7877 of 5 stars$38.85-1.2%$38.20-1.7%+201.9%$696.87M$179.28M7.18160Positive NewsShort Interest ↓Gap UpZBIOZenas BioPharma1.6507 of 5 stars$16.00-1.6%$36.67+129.2%N/A$673.77M$5M-4.51N/APositive NewsMYGNMyriad Genetics3.4951 of 5 stars$6.37+2.4%$12.45+95.5%-75.2%$592.69M$837.60M-1.492,700Positive NewsVSTMVerastem3.0856 of 5 stars$9.25+0.2%$13.29+43.6%+292.6%$569.29M$10K-2.8250EBSEmergent Biosolutions4.8186 of 5 stars$8.29-1.3%$14.33+73.0%+6.5%$442.81M$1.04B3.382,420Positive NewsAnalyst ForecastLXRXLexicon Pharmaceuticals2.2925 of 5 stars$1.10-4.3%$3.23+193.2%-32.9%$399.74M$31.08M-3.33140News CoverageAnalyst ForecastXOMAXOMA Royalty3.7335 of 5 stars$32.47-0.7%$69.50+114.0%+20.0%$392.49M$28.49M-20.9510Positive NewsCBIOCrescent Biopharma3.7413 of 5 stars$14.40+1.8%$25.60+77.8%N/A$281.52M$10K-0.4150 Related Companies and Tools Related Companies OPKO Health Competitors Geron Competitors Rigel Pharmaceuticals Competitors Zenas BioPharma Competitors Myriad Genetics Competitors Verastem Competitors Emergent Biosolutions Competitors Lexicon Pharmaceuticals Competitors XOMA Royalty Competitors Crescent Biopharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VNDA) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredFree: The Crypto Summit That Could Change Your Life27 industry leaders share urgent market intel (free access)... For a very limited time, you can claim your ...Crypto 101 Media | Sponsored“Shadow Group” in Washington, DC Could Crash MarketNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredTrump’s national nightmare is hereThe headlines are shocking: Washington has taken a $10 billion stake in one of America’s biggest chipmakers — ...Porter & Company | SponsoredWall Street Legend Names #1 ‘Hidden’ AI Stock50-year Wall Street legend says to forget NVDA. For the biggest potential gains, it's time to move your money ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vanda Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vanda Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
